SaraNM

Hepatology fellow @UHNTransplant PhD in NAFLD Immunology @Trinity_College Completed Specialty training in Gastroenterology @RCPI

[Elliot Tapper @ebtapper]

How many people visiting diabetes clinic have advanced liver fibrosis?

Lots

Laurent went to diabetes clinic and convinced 300 people to get a liver biopsy. 1 of every 3 had advanced fibrosis

These are the people at risk for liver cancer, ascites, encephalopathy #IMTLD2024

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Agile scores in MASLD and ALD

➡️External validation and their utility in clinical algorithms

Full text here👉https://t.co/uea2ML1TC5

@marg_p
#LiverTwitter

[Elliot Tapper @ebtapper]

People who smoke are more likely to develop liver fibrosis and cirrhosis

Here is a study in @HepCommJournal that explains why

https://t.co/ENWXLioxgc #livertwitter

[Journal of Hepatology @JHepatology]

🆕EASL #CPGs on the management of MASLD❗️

✅Update on definitions, prevention, screening, diagnosis & treatment for #MASLD

Full text👉https://t.co/DfkYMNEX29

✴️Joint publication with EASD & EASO❕

@EASLnews
@EASLedu
@AleksanderKrag
@DebbieShawcros1

[Laia Aceituno @laiaaas]

It's TODAY! 8.30h - 🎯MASLD clinical session
Come to discuss our results: the ANTICIPATE-NASH-LRE predicts better liver related events than the histology💥

[Elliot Tapper @ebtapper]

Would you like some expert recommendations for anticoagulation in atrial fibrillation and DVT/PE when it happens in #cirrhosis?

Yes?

Here you go

https://t.co/pQCVztyNzq

#livertwitter

[👩‍⚕️ Dr. Laura 👩‍⚕️ @datadriven_tdoc]

It turns out that if you see a female GI in consultation, over the next 2 years you are less likely to

➡️ end up in the ED

➡️ be admitted for GI-related indications

➡️ see your PCP

Why might that be?

Don’t know, but will be cool to find out!

[Laia Aceituno @laiaaas]

🤓Do you need an update on NIT to assess portal hypertension? Check out our latest review🚀 ⁦@LHuvh⁩ ⁦@EASLnews⁩ ⁦@AASLDtweets⁩ ⁦@BavenoCoop⁩ @juanbanares⁩ https://t.co/swlIllGClu

[Daniel J Drucker @DanielJDrucker]

The dynamic human hypothalamus #diabetes #obesity https://t.co/44I3cwQTJM

[American Journal of Transplantation @amjtransplant]

Original Article by Iske et al, "Transplanting old organs promotes senescence in young recipients"

https://t.co/3Jm3pyCp5b

[Daniel J Drucker @DanielJDrucker]

Beyond the weight room. The fascinating discussions, and related drug development efforts, surrounding loss of fat, and preservation of muscle in the treatment of #obesity #weightloss @IntJObesity https://t.co/Ed1rF3mFhq

[Keegan Figaro @FigaroKeegan]

Great work from @laiaaas and her colleagues 👏🏻🤌

https://t.co/B039LJyEvL

[JHEP Reports @JHEP_Reports]

🟪NEW Article in press❕

Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: a nationwide study

🔓#OpenAccess at 👉 https://t.co/qKQMEFx9md

#LiverTwitter

[Jonathan G. Stine, MD MSc, FACP @JonathanStineMD]

Take 2500 steps a day to cut your risk of developing #MASLD in half! Even a 20-minute walk can make a difference. #ExerciseIsKey #HealthTips #MASH #LiverTwitter #LiverX

[University of Toronto Gastroenterology+Hepatology @UofTGastroHep]

Congrats to Dr. Gideon Hirschfield and team for his spearheading a practice changing RCT on the role of Seladelpar in improving clinically relevant outcomes in patients with PBC with inadequate response to Ursodiol! Link below!

https://t.co/FYXVFLhXuK

[NEJM @NEJM]

Resmetirom is a selective agonist of THR-β. In adults with nonalcoholic steatohepatitis and fibrosis, daily resmetirom (80 mg or 100 mg) was superior to placebo with respect to NASH resolution and fibrosis improvement. Full MAESTRO-NASH trial results: https://t.co/Sa0XRPmU5C

[JHEP Reports @JHEP_Reports]

❕Liver transplant selection criteria and outcomes in critically ill patients with ACLF

🔓#OpenAccess at 👉 https://t.co/FHRIXtC5z7

#LiverTwitter

[Mads Israelsen @IsraelsenMads]

Our figure on the dynamic spectrum of steatotic liver disease & MetALD's role between MASLD & ALD gains data driven support!

Evidence of progressive risk across the spectrum is coming. Stay tuned!

@LancetGastroHep @AleksanderKrag @MajaThiele
link: https://t.co/ZNTMlG80Dd

[AASLD @AASLDtweets]

AASLD draft guidelines on NILDA are available for public comment through Jan. 1, 2024. https://t.co/e4KVq7jn5u

[Arndt Vogel @ArndtVogel]

Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis
@AGA_CGH
https://t.co/8fh0Pwyclk
👉3 pts with ICI induced hepatitis refractory to steroids, MMF & tacrolimus
🧐JAK inhibition appears to be effective for refractory ICI toxicities
@myESMO @ILCAnews @EASLnews #livertwitter